ArticleBMC biotechnology2026
Preparation, characterization, and evaluation of chitosan-thymol nanoparticles for antibacterial and antibiofilm activities against catheter-associated uropathogenic Escherichia coli.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uropathogenic Escherichia coli (UPEC) is a major cause of urinary tract infections (UTIs) and is capable of forming biofilms on inert surfaces, contributing to persistent and recurrent infections. Given the limitations of conventional antibiotics, alternative strategies are needed to control multidrug-resistant (MDR) UPEC. This study aimed to evaluate the antibacterial and antibiofilm effects of thymol-loaded chitosan nanoparticles (TLCNPs) against MDR UPEC isolates urinary catheters. TLCNPs were prepared using the ionotropic gelation method and characterized by scanning electron microscopy (SEM), dynamic light scattering (DLS), and Fourier-transform infrared spectroscopy (FTIR). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined using the broth microdilution method. Antibiofilm activity was assessed by the microtiter plate crystal violet assay. The relative expression of fimA and fimH genes was evaluated using real-time PCR. Cytotoxicity was assessed by the MTT assay on a human bladder carcinoma cell line (EJ138). The results showed that TLCNPs exhibited antibacterial activity against MDR UPEC isolates, with MIC and MBC values of 625 µg/mL. Biofilm formation was reduced by up to 76.2 ± 0.6% at ½ MIC concentration. Although a decrease in the relative expression of fimA and fimH genes was observed following treatment with TLCNPs, these changes were not statistically significant. Cytotoxicity assays indicated that more than 70% of EJ138 cells remained viable after 24 h, and over 50% after 48 h at ½ MIC. Overall, this study evaluated the antibacterial, antibiofilm, and preliminary safety profile of thymol-loaded chitosan nanoparticles against MDR UPEC, providing experimental data for their further investigation as a potential adjunct approach for biofilm-associated UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.